key: cord-0069362-ffu43d7u
authors: nan
title: Plasmin Cascade Mediates Thrombotic Events in SARS-CoV-2 Infection via Complement and Platelet-Activating Systems
date: 2020-08-06
journal: IEEE Open J Eng Med Biol
DOI: 10.1109/ojemb.2020.3014798
sha: f3fe11ca8bd4b1eeb65a28820f48333d979ebc27
doc_id: 69362
cord_uid: ffu43d7u

Objective: Recently emerged beta-coronavirus SARS-CoV-2, has resulted in the current pandemic designated COVID-19. COVID-19 manifests as severe illness exhibiting systemic inflammatory response syndrome, acute respiratory distress syndrome (ARDS), thrombotic events, and shock, exacerbated further by co-morbidities and age. Recent clinical evidence suggests that the development of ARDS and subsequent pulmonary failure result from a complex interplay between cell types (endothelial, epithelial and immune) within the lung promoting inflammatory infiltration and a pro-coagulative state. How the complex molecular events mediated by SARS-CoV-2 in infected lung epithelial cells lead to thrombosis and pulmonary failure, is yet to be fully understood. Methods: We address these questions here, using publicly available transcriptomic data in the context of lung epithelia affected by SARS-CoV-2 and other respiratory infections, in vitro. We then extend our results to the understanding of in vivo lung, using a publicly available COVID-19 lung transcriptomic study. Results and Conclusions: Our analysis indicates that there exists a complex interplay between the fibrinolytic system particularly plasmin, and the complement and platelet-activating systems upon SARS-CoV-2 infection, with a potential for therapeutic intervention.

serine protease (TMPRSS2) [13] , [14] , thus contributing to the increased transmissibility and lower-lung pathogenicity in humans [15] . This observation led us to explore mechanisms unique to SARS-CoV-2 infection of lung epithelial cells and cause thrombotic events.

In this study, we utilized publicly available RNA-sequencing data [5] (GSE100457) from Normal Human Bronchial Epithelial (NHBE) cell lines infected with SARS-CoV-2 (henceforth referred to as the CoV-2 dataset) and compared it with lung epithelial cells infected with other respiratory infections, namely, respiratory syncytial virus (RSV), influenza (H1N1), and rhinovirus (RV16) using stringent study inclusion criterion (see Methods). Differentially expressed genes (DEGs) were called for each infection (with respect to their respective controls) using limma/voom, at an adjusted p-value < 0.05 (see Methods). We identified a total of 339, 27, 1781, and 208 DEGs in CoV-2, RSV, H1N1 and RV16 datasets, respectively, with a more significant proportion of genes upregulated, in all cases, in response to infection (Supplementary Table 1 ). Our analysis indicated a significant over-representation of functional categories associated with immune response, across all infections (among upregulated genes) (Fig. 1) . The categories included, "response to virus", "TNFα signaling via NFκB", "interferon response" (types I/α, II/γ ), and "apoptosis". However, "coagulation" and "keratinocyte differentiation pathways" were among the top pathways to be uniquely enriched within the CoV-2 dataset. Genes including ANXA1, C1S, C3, CFB, F3, ITGB3, MAFF, MMP1, MMP9, PDGFB, PLAT, PLAU, SERPINB2, TFPI2 associated with "coagulation" and S100A7, ANXA1, TGM1, IVL, and small prolinerich proteins SPRR2A, SPRR2E, SPRR2D, associated with the "keratinocyte differentiation pathway" were among the 161 genes that were "uniquely" significantly upregulated within the CoV-2 dataset (Fig. S1 ). Keratinocytes are known to be associated with epithelial cell repair.

We posed the question if analyzing the molecular cascades associated uniquely with SARS-CoV-2, identified above, could translate to findings that are relevant to thrombotic outcomes seen in severe/acute COVID-19 patients [16] . To relate the clinical and molecular phenotypes associated with SARS-CoV-2 infection, we generated a protein interaction map (strength > 0.85) from DEGs identified within the CoV-2 dataset (see Methods). We annotated this network with data from the comparative analysis for the three other infections (RSV, RV16, and H1N1). We subsequently clustered this network, to identify "functional modules" relevant to the pathology of SARS-CoV-2 infection. Our clustering identified nine modules with five smaller functional modules containing genes associated uniquely with SARS-CoV-2, involving angiogenesis, tubulins, keratinocytes, and small proline-rich proteins (Fig. 2) . Three of the four remaining modules were mainly associated with immune response. These functional modules included (i) genes associated with response to IFN type I/III such as IFITM1, IFITM3, MX1, MX2, OAS1, OAS2, IFIT1, IFIT3, and IRF9; (ii) Activation of the IL-17 proinflammatory cascades (IL6, IL1B, and CXCL1) via the TNFα and NFκB signaling cascades (TNF, CSF2, CSF3, NFKB1, NFKB2, RELB, and IRAK2) (iii) Signaling cascades downstream of interleukin response including JAK-STAT containing genes such as IL6R, STAT1, SOCS3, IFNGR1, and PDGFB. Interestingly, though these modules were broadly representative of vital immune mechanisms seen in all respiratory infections [17] , [18] , they also highlighted specific mechanisms unique to SARS-CoV-2. For example, subversion of innate immune response is inherent to cytopathic pathogens like SARS-CoV (a related beta coronavirus), which causes an increased release of pyroptosis products (e.g. IL-1B), inducing acute inflammatory responses. The antagonism of an interferon response by SARS-CoV viral proteins has been suggested to occur at multiple stages of the interferon and NFKB signaling cascades, through multiple mechanisms, including IKBKE and TRAF3 regulation, affecting downstream STAT1 associated signaling [19] . It is possible that, in the SARS-CoV-2 infection, the observed upregulation of IKBKE, TRAF3, NFKB1, NFKB2, RELB, and IRAK2 at 24hpi could be a consequence of similar mechanisms [2] The fourth large module, contained genes specifically activated within the CoV-2 dataset, involved in fibrinolysis and plasminogen activation cascades (PLAT, PLAU, PLAUR, and SERPINB2), the complement activation cascade including C3, CSB, CXCL5, and platelet aggregation (platelet activation factor receptor-PTAFR (Fig. 2) ). This module was particularly noteworthy given the enrichment results (Fig. 1A) and clinical findings of COVID-19 [16] . It is analyzed further in the following sections.

Plasminogen is the precursor of the serine protease plasmin, a vital component of the fibrinolytic system, essential for ensuring immune cell infiltration and cytokine production [20] . Plasminogen can be activated to plasmin by two serine peptidases, the tissue tissue-specific (T-PA) and urokinase (U-PA) plasminogen activators encoded by PLAT and PLAU, respectively. It has been previously reported for SARS-CoV and influenza infections that dysregulation of the urokinase pathway including U-PA(PLAU) and its inhibitor PAI-1(SERPINE1) might contribute to the severity of lung disease by altering the dynamics of fibrin breakdown and intra-alveolar fibrin levels and subsequently inflammation [21] , [22] . We observed a similar dynamic with SARS-CoV-2 infection albeit through activation of tissue plasminogen, PLAT, and the inhibitor SER-PINB2. T-PA (which is triggered when bound to fibrin) and F3 (tissue factor, activated in CoV-2) levels are known to correlate with d-dimer levels [23] . D-dimer, a product of fibrin degradation by plasmin, is elevated in patients with COVID-19 and has been identified as a marker for disseminated intravascular coagulopathy and a worse patient prognosis [24] . These findings indicate increased fibrinolytic activity, specifically via T-PA (PLAT) activation, in SARS-CoV-2 infections.

The outcome of any viral infection is mediated through a complex interplay between viral and host proteins, which allow for a coordinated innate immune response. Plasminogen inhibitor (PAI)-1 (SERPINE1) has been reported to function as an anti-viral factor capable of inhibiting extracellular maturation of influenza particles, specifically through their action on TMPRSS2 [25] . A similar mechanism involving PAI-2 (SERPINB2) likely exists in SARS-CoV-2 infections. Additionally, T-PA (PLAT) has been reported to interact with ORF8 protein of SARS-CoV-2 virus [2] ; however, its consequence has not yet been elucidated. We hypothesize that if this interaction titrates out T-PA, it is likely to result in reduced levels of plasmin, which could contribute to downstream thrombosis events, as observed in COVID-19 patients [16] . Increased expression of PLAT validated this. Additionally, increased concentration of SERPINB2 is also likely to reduce plasmin levels leading to thrombosis. The unique regulation of SERPINB2 and PLAT in SARS-CoV-2 infections and their subsequent effect on viral-host interaction dynamics is worthy of further investigation.

Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that facilitate leukocyte infiltration by breaking down the extracellular matrix (ECM) and basement membrane. The genes MMP1 and MMP9 (both upregulated specifically within the CoV-2 dataset, see Fig. 2 ) can also be activated by plasmin in vivo and in vitro [26] . Additionally, the degranulation of neutrophils by T-PA has been indicated as a source for the increase of matrix metalloproteinase 9 (MMP-9) [27] . Given the observed increase in MMPs, and their role in facilitating lung inflammation in ARDS (by enabling neutrophil migration and ECM breakdown) [28] , it will be essential to evaluate the impact of T-PA treatments [29] on pulmonary remodeling (via MMPs) in patients with severe/acute COVID-19.

We identified significant upregulation of several genes encoding components of the complement system, including C3, CFB, and C1S, uniquely within the CoV-2 dataset, in contrast to other upper respiratory tract infections (at 24 hpi). The complement pathway is an integral part of the innate immune response and is involved in immunosurveillance for pathogen clearance (bacterial and many viral) [30] . It traditionally serves as a vital link between the innate and the adaptive immunity, mainly driving pro-inflammatory cascades. Several chemokines/chemoattractants (CXCL5, CXCL6, CXCL3, and CCL20) identified within this cluster can also be activated by signaling events precipitated by complement activation [31] , p. 5]. Overstimulation of these chemokines, particularly CXCL5, is known to cause destructive inflammatory lung conditions in specific pathogenic models of lung disease [32] .

Plasmin is known to activate complement cascade independently of established pathways (alternate, lectin, and classical pathways) by cleaving C3 and C5 to functional anaphylatoxins C3a and C5a, in vitro and animal model studies [33] . Furthermore, there is increasing evidence for the role of complement in coagulation. C3 binds fibrinogen and fibrin with high affinity and prolonging fibrinolysis in a concentration-dependent manner [34] . Studies in animal models of thrombosis have identified a plasmin-driven C5a generation capable of driving procoagulant cascades [35] . Moreover, the presence of terminal complement components including C5b-9 (membrane attack complex/MAC), C4d, and mannose-binding lectin (MBL)-associated serine protease (MASP2) within the pulmonary microvasculature and purpuric skin lesions of deceased COVID-19 patients [36] . MAC has been additionally suggested to promote neutrophil adhesion via platelet activating factor (PAF)-mediated mechanisms [37] . We observe a unique activation of the PAF receptor (PAFR, encoded by the gene PTAFR) within the complement and coagulation cluster (Fig. 2) . PAF is a potent activator of platelet aggregation as well as immune cell types including macrophages and neutrophils [38] . PAF binding to PAFR activates several intracellular signaling events including complement activation [39] , and plays pathophysiological roles in molecular mechanisms underlying anaphylaxis, bronchial asthma, cystic fibrosis [40] , and endotoxin shock/sepsis [41] . It is a crucial mediator of systemic and pulmonary hemodynamic changes, additionally contributing to pulmonary edema [42] , [43] fitting the COVID-19 lung injury model [44] . Immune infiltration primed by interaction between complement system and PAF has been reported previously. Specifically, C5a and PAF together can induce massive eosinophil transmigration [45] . Eosinophils release leukotrienes and lipids, which can cause further epithelial damage and airflow obstruction [46] . Leukotrienes, C5a, and PAF are also potent chemo-attractants of polymorphonuclear leukocytes (neutrophils or PMNs), which can further activate neutrophil extracellular traps (NETs) leading to pulmonary damage seen in COVID-19 patients [47] . Given the ubiquity of SARS-CoV-2 receptors and its ability to infect a broad range of cell types [13] , analysis of PTAFR activation patterns in infected tissues (including vascular endothelial cells) could provide further insights into increased platelet aggregation (via PAF signaling) and the risk for arterial thrombosis seen in severe/acute COVID-19 patients [16] . Vitamin-D is known to attenuate ICAM1 and PTAFR expression and subsequently NFκB mediated inflammation, in rhinovirus infections [48] . ICAM1 is a crucial mediator of inflammation and is suggested to mediate eosinophil adhesion to airway epithelium [49] . Similar mechanisms can underly the recent reports on reduced risk for COVID-19 infections after Vitamin-D supplementation, and provide evidence for PAF/PAFR mediated signaling in the progression of COVID-19 [50] .

The significant enrichment of mechanisms identified above were indicative of active epithelial remodeling and provided evidence for a plasmin-mediated complement activation within SARS-CoV-2 in contrast to other respiratory infections. We also identified mechanisms that might contribute to increased inflammation via immune infiltration and platelet aggregation, primed by the interactions between the complement system, plasmin and the PAF/PAFR. Our findings further the understanding of modulation of hemostatic factors, affecting the mechanics of circulating fibrin and fibrin breakdown products [3] and complement activation, underlying acute thrombotic events including arterial thrombosis in COVID-19 patients [16] .

In addition, analysis of DEGs from transcriptomic measurements in postmortem lung tissue from COVID-19 patients provided a partial insight into the mechanisms associated with virus-altered epithelial function. Functional analysis of DEGs identified with COVID-19 exhibited an upregulation of similar immune cascades as those identified within the CoV-2 dataset (Figs. S2 and S3 ). Significant correlation was also identified for foldchanges between DEGs commonly regulated between COVID-19 lung and CoV-2 dataset (rho = 0.34). We present our current view of the crosstalk between plasminogen, complement and platelet-activating systems in SARS-CoV-2 infection in Fig. 3 .

We are cognizant that we cannot wholly ascribe all mechanisms observed within a single time point (24 hpi) as contributing to observed clinical pathology of COVID-19, given the limited availability of relevant publicly available human in vitro data. However, our analysis highlighted SARS-CoV-2 driven response of healthy lung epithelial cells and its ability to incite a misdirected cascade of interactions between the coagulation, complement activation, and proteins involved in the fibrinolytic system. Using current knowledge of these three systems and the analysis of the data from in vitro model systems we infer the consequences of this misdirected network of interactions, namely, coagulation, inflammation, and vascular leakage/pulmonary edema in the COVID-19 lung. Detailed in vivo and in vitro studies will be required to better understand the viral-host dynamics with respect to T-PA (PLAT) and PAFR (PTAFR) activation and the subsequent systemic inflammatory responses, in symptomatic and asymptomatic COVID-19 populations.

Our analysis hypothesizes that managing the equilibrium between the complement, coagulation and platelet-activating components can determine the overall biological activity and the outcome of a disease severity in COVID-19. An investigation into the efficacy of complement inhibitors (such as Eculizumab [51] or Compstatin [52] ), and plasminogen activators specifically for T-PA, combined with Vitamin-D supplementation to alleviate symptoms in patients with severe/acute COVID-19, warrant exploration.

We analyzed the data recently published by Blanco-Melo et al. [5] to gain mechanistic insights into the pathogenicity of SARS-CoV-2. The published dataset contained multiple cell lines treated with SARS-CoV-2 including NHBE, Calu-3, A529 (with and without exogenous expression of ACE2) in addition to COVID-19 lung and normal tissue samples (available via GSE147507). Histogram of counts within normal and diseased lung samples indicated that one COVID-19 lung sample (Covid Lung 2, Fig. S4 ) is a likely an outlier and was ignored from further analysis. Based on the sample clustering results of the raw counts ( Fig. S2 .B), we limited our analysis to NHBE/ normal human bronchial epithelial cell lines (hence forth referred to as the CoV-2 dataset). All available series (GSE) in GEO were extracted from the gene expression omnibus with key words-"SARS-CoV", "MERS-CoV", "RSV" or "respiratory syncytial virus", "Influenza" and "Rhinovirus" for respiratory cell lines (NHBE or BEAS-2B). Since the CoV-2 transcriptional data was processed at 24 hpi (hours post infection), we chose to compare only those infections which had cell-lines at 24 hpi yielding the following series GSE3397, GSE71766, GSE100504, GSE81909, GSE27973, and GSE28904. To limit the impact of sequencing technologies, we utilized only Affymetrix, the technology with the most coverage among the series considered. Applying the above stringent inclusion criteria yielded 3 GEO series GSE3397 [53] (RSV), GSE71766 [54] (Influenza/H1N1 and Rhinovirus/RV16) and GSE27973 [55] (Rhinovirus/RV16). We, however, did not find studies on related beta-coronaviruses in NHBE/BEAS-2B cell lines which matched our inclusion criterion.

For the sake of reproducibility, we called differentially expressed genes (DEGs) at adjusted p.value <0.05, using GEO2R for GSE3397, GSE71766 and GSE27973 comparing infected cells with their respective mocks at 24 hpi only. The DEGs called for GSE27973 were a subset of GSE71766 RV16 comparisons and subsequently ignored. Since these were microarray studies, we aggregated probes which were significantly differentially expressed, to gene names and calculated a mean fold change (Supplementary Table 1 ) and considered these for all comparisons outlined in the manuscript. We utilized the same pipeline implemented in GEO2R to call DEGs from CoV-2 data (using the limma-voom pipeline in R). Low counts were filtered using the "FilterByExpression" feature available through the edgeR package. "topTable" was used to extract all samples under our significance threshold of p.adj <0.05. We would additionally like to point out that we reanalyzed the CoV-2 data using the DESeq2 protocol as described in the original publication consistently identified similar number of DEGs as detected through limma-voom. For the comparision of COVID-19 lung biopsy sample against two healthy tissue biopsies, we utilized the exact T-test via "edgeR" to establish significance and extracted the significant genes via "topTags".

The human protein-protein interaction network (PPIN) was downloaded from STRINGdb (v 11.0) [56] for a combined edge strength of >0.85. We extracted a SARS-CoV-2 infection relevant subnetwork from this PPIN using DEGs identified in the CoV-2 dataset. The resulting CoV-2 network contained 272 nodes and 608 edges (Fig. S3 ). We additionally annotated this CoV-2 network with differential gene expression information (foldchange) identified in all infections, if present, to allow us to identify DEGs unique to CoV-2. Functionally relevant modules within this network were extracted using GLay clustering [57] . GLay is an implementation of the Girvan-Newman fast greedy community clustering algorithm. Girvan-Newman algorithm identifies communities by progressively pruning of edges to identify most densely connected clusters. Clusters with >3 nodes were retained for further analysis, resulting in a network size of 186 nodes and 9 clusters (Fig. 2) . The clusters were named based on the most prominent terms associated with each cluster as identified using Enrichr [58] . All network analysis and clustering (via the clusterMaker plugin) was performed in Cytoscape [59] . Functional enrichment was performed using gene ontology (biological process) and mSigDB's Hallmark genesets (v7.1). All visualizations were generated via the ClusterProfiler library [60] available through R/Bioconductor.

Supplementary figures (S1-S4) and an Excel file containing supplementary tables identified in the main manuscript are included online.

Structural and functional basis of SARS-CoV-2 entry by using human ACE2

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure

Clinical characteristics of Covid-19 in New York city

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

The trinity of COVID-19: Immunity, inflammation and intervention

A single-cell atlas of the peripheral immune response to severe COVID-19

Complex immune dysregulation in COVID-19 patients with severe respiratory failure

Lung pathology of severe acute respiratory syndrome (SARS): A study of 8 autopsy cases from Singapore

Influenza virus-induced lung injury: Pathogenesis and implications for treatment

Pathology and pathogenesis of severe acute respiratory syndrome

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Cell entry mechanisms of SARS-CoV-2

COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and followup

Host immune response to influenza A virus infection

Modulation of the immune system by human rhinoviruses

Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-κB signaling

Plasmin: A modulator of immune function

Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury

Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis

Genetic predictors of fibrin D-dimer levels in healthy adults

D-dimer is associated with severity of coronavirus disease 2019: A pooled analysis

A serpin shapes the extracellular environment to prevent influenza a virus maturation

Matrix metalloproteinases and cellular fibrinolytic activity

Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release

Kinetics and role of plasma matrix metalloproteinase-9 expression in acute lung injury and the acute respiratory distress syndrome

Tissue plasminogen activator (tpa) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series

Structure and biology of complement protein C3, a connecting link between innate and acquired immunity

The mysterious ways of the chemokine CXCL5

CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis

Interaction between the coagulation and complement system

Complement C3 is a novel plasma clot component with anti-fibrinolytic properties

Complement activation in arterial and venous thrombosis is mediated by plasmin

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Neutrophil adhesion to human endothelial cells is induced by the membrane attack complex: The roles of P-selectin and platelet activating factor

Platelet-Activating Factor (PAF)

Platelet activation leads to activation and propagation of the complement system

Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells

Platelet-activating factor receptor

Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxintreated rats

Platelet-activating factor causes neutrophil accumulation and edema in rabbit lungs

COVID-19 lung injury and high altitude pulmonary edema: A false equation with dangerous implications

Triple role of platelet-activating factor in eosinophil migration across monolayers of lung epithelial cells: Eosinophil chemoattractant and priming agent and epithelial cell activator

The role of eosinophils and neutrophils in inflammation

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

Vitamin D attenuates rhinovirus-induced expression of intercellular adhesion molecule-1 (ICAM-1) and plateletactivating factor receptor (PAFR) in respiratory epithelial cells

A CD18/ICAM-1-dependent pathway mediates eosinophil adhesion to human bronchial epithelial cells

Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths

Eculizumab treatment in patients with COVID-19: Preliminary results from real life ASL Napoli 2 Nord experience

Complement as a target in COVID-19?

Identification of gene biomarkers for respiratory syncytial virus infection in a bronchial epithelial cell line

A systems approach to understanding human rhinovirus and influenza virus infection

Cigarette smoke modulates expression of human rhinovirus-induced airway epithelial host defense genes

STRING v9. 1: Protein-protein interaction networks, with increased coverage and integration

GLay: Community structure analysis of biological networks

Enrichr: A comprehensive gene set enrichment analysis web server 2016 update

Cytoscape: A software environment for integrated models of biomolecular interaction networks

clusterprofiler: An R package for comparing biological themes among gene clusters